Sodium, Potassium, Blood Pressure, and Cardiovascular Disease in Humans

被引:0
作者
Paul K. Whelton
机构
[1] Tulane University School of Public Health and Tropical Medicine,Department of Epidemiology
来源
Current Hypertension Reports | 2014年 / 16卷
关键词
Sodium; Potassium; Blood pressure; Cardiovascular disease;
D O I
暂无
中图分类号
学科分类号
摘要
The scientific underpinning for recommended levels of dietary sodium and potassium intake is of great importance to healthcare providers and policy decision-makers. Recent clinical trials and meta-analyses confirm the capacity of dietary sodium reduction and potassium supplementation to reduce blood pressure with no harmful effects on blood lipid levels in customary clinical settings. Blood pressure is thought to be a good surrogate for cardiovascular disease events and the most important preventable risk factor for mortality and disability-adjusted life years. Cohort analyses and related pooling studies that have been used to explore the relationship between dietary Na and CVD were all based on secondary analyses of datasets that were not designed for this purpose. Most are of insufficient quality to provide dependable information. The limited information available from clinical trial experience and cohort studies of higher quality suggests a reduction in dietary Na decreases CVD morbidity and mortality. Modeling studies suggest that a small reduction in dietary sodium would result in a sizable general population health benefit. Some countries have experienced a progressive decline in average dietary sodium consumption. However, there is no evidence of a corresponding trend in the United States, and almost the entire population is failing to meet dietary sodium and potassium guideline recommendations.
引用
收藏
相关论文
共 198 条
[1]  
Lewington S(2003)Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 361 1903-13
[2]  
Clarke R(1993)Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Intern Med 153 598-615
[3]  
Qizilbash N(2009)Premature deaths attributable to blood pressure in China: a prospective cohort study Lancet 374 1765-72
[4]  
Stamler J(1999)Are surrogate markers adequate to access cardiovascular disease drugs? JAMA 282 790-5
[5]  
Stamler R(2006)Blood pressure as an example of a biomarker that functions as a surrogate AAPS J 8 E146-52
[6]  
Neaton JD(2012)Biomarkers and surrogate endpoints in clinical trials Stat Med 31 2973-84
[7]  
He J(2012)Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomized controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (Biosurrogate) evaluation schema (BSES) BMC Med Res Methodol 12 27-23
[8]  
Gu D(2005)Global burden of hypertension: analysis of worldwide data Lancet 365 217-13
[9]  
Chen J(1995)Prevalence of hypertension in the U.S. adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991 Hypertension 25 305-60
[10]  
Temple R(2012)A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Lancet 380 2224-20